17-Alpha hydroxyprogesterone in Multiple pregnancies to Prevent Handicapped InfAnts

Conditions

Multiple pregnancy Pregnancy and Childbirth Multiple pregnancy

Noor E. Simons, Emilie V J van Limburg Stirum, Aleid G. van Wassenaer‐Leemhuis, Martijn J.J. Finken, Cornelieke S.H. Aarnoudse-Moens et al. (15 authors)

BMJ Open2021-09-013 citations

10.1136/bmjopen-2021-053066

Pessary placement in the prevention of preterm birth in multiple pregnancies: a propensity score analysis.

Monfrance MJ, Schuit E, Groenwold RH, Oudijk MA, de Graaf IM, Bax CJ, Bekedam DJ, Mol BW, Langenveld J.

2015-11-303 citations

10.1016/j.ejogrb.2015.11.001

17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.

Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenwold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW.

2011-09-0160 citations

10.1097/aog.0b013e31822ad6aa

Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.

Lim AC, Bloemenkamp KW, Boer K, Duvekot JJ, Erwich JJ, Hasaart TH, Hummel P, Mol BW, Offermans JP, van Oirschot CM, Santema JG, Scheepers HC, Schöls WA, Vandenbussche FP, Wouters MG, Bruinse HW, AMPHIA study group.

2007-06-1914 citations

10.1186/1471-2393-7-7

Interventions

Participants will receive weekly intramuscular injections of 17OHPC or placebo, starting at a gestational age between 16 and 20 weeks and continuing until 36 weeks. Cervical length will be measured at

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women with a multiple pregnancy 2. Gestational age between 15 and 19 weeks 3. Aged 18 and older

Exclusion criteria

Exclusion criteria: 1. Major congenital anomaly of (one of) the fetuses 2. Death of (one of) the fetuses 3. Early signs of Twin-to-Twin Transfusion Syndrome 4. Primary cerclage 5. Previous preterm birth less than 34 weeks

Design outcomes

Primary

Measure	Time frame
The primary outcome will be composite neonatal morbidity, containing severe Respiratory Distress Syndrome (RDS), BronchoPulmonal Dysplasia (BPD), intraventricular haemorrhage stage IIB or worse, Necrotising EnteroColitis (NEC), proven sepsis and death before discharge.	—

Secondary

Measure	Time frame
Secondary outcome measures are: 1. Time to delivery 2. Preterm birth rate before 32 and 37 weeks 3. Days of admission in neonatal intensive care unit 4. Maternal morbidity 5. Maternal admission days for preterm labour 6. Costs	—

Countries

Netherlands

Outcome results

None listed